New Study Confirms Typhoid Vaccine Safety, Immune Response in Children

Published: Aug. 10, 2022 at 8:10 AM EDT

Vaccine does not interfere with routine measles-rubella vaccine in Malawian children

BLANTYRE, Malawi, Aug. 10, 2022 /PRNewswire/ -- A new study, published in The Lancet Global Health, finds the typhoid conjugate vaccine, Typbar TCV®, provides immunity for up to three years in children as young as nine months old in Malawi. The research – conducted by the Blantyre Malaria Project, Malawi-Liverpool-Wellcome Trust, and researchers at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) – found that the TCV vaccine is safe and well tolerated. Importantly, the vaccine can be given to nine-month-old infants at the same time as routine measles-rubella vaccinations without reducing the immune response to either vaccine.

The newly published research is a double-blind, randomized, controlled clinical trial done in Blantyre, Malawi. The study team randomly assigned 631 children with no immunosuppression or chronic health conditions to either receive the TCV typhoid vaccine or a vaccine for meningococcal serogroup A conjugate, which is routinely used in Africa. The typhoid vaccine showed strong immune responses against typhoid in children ages nine months to 12 years old.

"It is simply amazing that a single dose of TCV will protect Malawian children for years," said Ngina Nampota, MBBS, MS, lead author of the new research and Study Physician with the Blantyre Malaria Project, an affiliate of Kamuzu University of Health Sciences, Malawi.

Typhoid causes more than nine million cases and at least 110,000 deaths worldwide every year, most of which occur in sub-Saharan Africa and southeast Asia. It is transmitted by ingesting contaminated food or water, often due to lack of safe water and sanitation.

The new study is supported by TyVAC – a partnership between CVD, the Oxford Vaccine Group at the University of Oxford, and the global non-profit PATH. TyVAC aims to accelerate the introduction of the TCV vaccine as part of an integrated approach to reduce the burden of typhoid in countries eligible for support from Gavi, the Vaccine Alliance. TyVAC was initiated in 2016 as a multi-country project to accelerate the introduction of the TCV vaccine in Gavi-eligible countries.

"TCVs are the first vaccines that protect children as young as six months of age against typhoid. This study is one of the first to demonstrate a long-lasting immune response in African children who are disproportionately affected by typhoid and its potential consequences, including death," said Matthew B. Laurens, MD, MPH, Professor of Pediatrics and Medicine at UMSOM and senior author of the new research. "TCVs will ensure children in affected areas can lead healthier, productive lives free of typhoid."

These vaccines offer an easy – and World Health Organization-approved – way to control this devastating disease and save lives. Data from a phase 3 clinical trial in Malawi, published in September 2021 in The New England Journal of Medicine, also showed that this vaccine is a safe and effective way to protect children under age 15, the population most affected by typhoid. The new Lancet Global Health research is a "substudy" of this larger clinical trial.

Additionally, the new study showed that children under one year of age had both a strong immune response and no significant side effects when TCV was given alongside a routine measles-rubella vaccine. In countries with limited access to health care and transportation, the ability to administer multiple vaccines in one visit improves access to preventive care. Children who receive TCV typically experience mild side effects, most commonly injection-site pain. These reactions are consistent with other similar vaccines.

"TCVs provide a ray of hope in resource-limited settings, where children are disproportionately impacted by typhoid," said Kathleen Neuzil, MD, MPH, the Myron M. Levine, MD, DTPH, Professor in Vaccinology at UMSOM and coauthor of the current study. "With broad use of TCVs, combined with improved water and sanitation, we have the ability to make typhoid a disease of the past." Dr. Neuzil is also the director of CVD at UMSOM and principal investigator for TyVAC.

The next steps, Dr. Laurens said, are to assess the effect of a booster dose on long-term protection from typhoid fever in children. While researchers continue to monitor the children vaccinated as part of this study, previous research suggests that TCV protection likely lasts at least five years.

"Our team's goal to protect children against typhoid represents a long-term aim of scientists working across the globe," said Mark T. Gladwin, MD, Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean at UMSOM. "We are proud of these life-saving accomplishments of scientists in the University of Maryland's Center for Vaccine Development and Global Health, who are focused on global efforts to reduce health care disparities."

The Bill & Melinda Gates Foundation partially funded this study with grant OPP1151153. Typbar TCV® is licensed by Bharat Biotech International Limited, Hyderabad, India.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System ("University of Maryland Medicine") has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

About the Center for Vaccine Development and Global Health

For over 40 years, researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world's underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has worked to eliminate vaccine-preventable diseases. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, malaria, and other infectious diseases. CVD's research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. CVD researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact. Currently, these diseases include typhoid, Shigella, E. coli diarrhea, malaria, and other vaccine-preventable infectious diseases. CVD researchers have been involved in critical vaccine development for emerging pathogens such as Ebola and Zika. In addition, CVD's work focuses on the ever-growing challenge of antimicrobial.

View original content:

SOURCE University of Maryland School of Medicine

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.